Partnership follows successful scale-up of CHO Edge System by LOTTE BIOLOGICS
Boston, Massachusetts, and Syracuse, New York – Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, and LOTTE BIOLOGICS, a global CDMO, today announced a strategic partnership focused on accelerating cell line development and scaling to GMP manufacturing, having demonstrated successful scale-up.
This collaboration combines Asimov's advanced CHO Edge cell line development platform with LOTTE BIOLOGICS' robust large-scale manufacturing services, significantly increasing efficiency and speed from development to production for therapeutic developers.
James Park, LOTTE BIOLOGICS CEO and Alec Nielsen, Asimov co-founder and CEO at the Memorandum of Understanding Signing Ceremony on 12th March 2025
Alec Nielsen, Asimov co-founder and CEO, said: “We’re delighted to be directly integrating with LOTTE BIOLOGICS’ established manufacturing capabilities, meaning our customers can now transition seamlessly from cell line development to large-scale GMP production, and drastically shorten their development cycles.”
James Park, LOTTE BIOLOGICS CEO, commented: “We believe this agreement will unlock the full potential of both companies’ strengths. By combining Asimov’s cutting-edge technology with LOTTE BIOLOGICS’ manufacturing excellence, we will not only deliver unparalleled services to our customers but also drive innovation in the biopharmaceutical industry. Ultimately, our goal is to make a meaningful impact on patients’ lives, and we will continue striving to be a company that contributes to a healthier future for all.”
Highlights
Virtual Private Network (VPN): Users connect to the cluster, provide some credentials and are then able to access internal tools.
Single Sign-On: A tool like Kerberos allows you to use the same account across various components.
Home-grown user accounts: You implement an authentication system and users have a separate username/password for your computing infrastructure.
Asimov, the synthetic biology company building a full-stack platform to program living cells, announced today it has been awarded a contract as part of the Defense Advanced Research Projects Agency (DARPA) Automating Scientific Knowledge Extraction (ASKE) opportunity.
Through ASKE, Asimov will work to develop a physics-based artificial intelligence (AI) design engine for biology. The goal of the initiative is to improve the reliability of programming complex cellular behaviors.
“To achieve truly predictive engineering of biology, we require dramatic advances in computer-aided design. Machine learning will be critical to bridge genome-scale experimental data with computational models that accurately capture the underlying biophysics. As genetically engineered systems grow in complexity, they become difficult for humans to design and understand. For simple genetic systems with only a couple of genes, synthetic biologists typically use high-throughput screening and basic optimization algorithms. But to engineer more complex applications in health, materials, and manufacturing, we need radically new algorithms to intelligently design the DNA and simulate cell behavior.”
Alec Nielsen, Phd, Asimov CEO
Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.
Asimov’s founders previously built a hybrid genetic engineering and computer-aided design platform called Cello to program logic circuit behaviors in cells. The ASKE opportunity will seek to support an ambitious expansion in the types of biological behaviors that can be engineered. Asimov’s approach will leverage “multi-omics” cellular measurements, structured biological metadata, and novel AI architectures that combine deep learning, reinforcement learning, and mechanistic modeling. Over the past year, the company has ramped up hiring in experimental synthetic biology, machine learning, and data science to accelerate development of their genetic design platform.
Highlights
Headering 3
DARPA recently announced a multi-year investment of $2B into innovative artificial intelligence research called the AI Next campaign. A part of this wide-ranging AI strategy is DARPA’s Artificial Intelligence Exploration program, which was developed to help expeditiously move pioneering AI research from idea to exploration in fewer than 90 days. DARPA’s ASKE opportunity is part of this program and is focused on developing AI technologies that can reason over rich models of complex systems.
“Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.”